{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:24:14Z","timestamp":1789514654549,"version":"build-2803163510"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Tumour lysis syndrome (TLS) is a significant complication of haematologic malignancies and their management. The syndrome consists of laboratory abnormalities either alone (laboratory TLS) or with clinical sequelae including renal failure, seizures, and arrhythmias (clinical TLS). Clinical TLS is a predictor for worse overall morbidity and mortality in cancer patients, but can be prevented. Thus, accurate prognostication is critical to appropriate management of patients at risk for TLS, and incorporates both disease factors (tumour type and burden) and patient factors (baseline renal insufficiency or hyperuricaemia). Strategies to prevent TLS include hydration and allopurinol in low\u2010 and intermediate\u2010risk patients and rasburicase in high\u2010risk patients.<\/jats:p>","DOI":"10.1111\/bjh.16278","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T10:41:39Z","timestamp":1574851299000},"page":"494-500","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Emergencies in haematology: tumour lysis syndrome"],"prefix":"10.1111","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-2424","authenticated-orcid":false,"given":"Urshila","family":"Durani","sequence":"first","affiliation":[{"name":"Department of Medicine Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"AbbVie Inc. (2018)Venclexta (venetoclax) [package insert]. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208573s009lbl.pdf."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(86)80387-0"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0556-x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-016-0969-5"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11612"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08143.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2016.10.040"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0055"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0177"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.09.045"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196603032740902"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25000"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0147"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(63)90010-9"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.2998"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199807)31:1<27::AID-MPO6>3.0.CO;2-1"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12327"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(68)80209-4"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.217380"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9620520"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403566"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00860751"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0576-y"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019422"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1951.63670170004011c"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500404662"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11575"},{"key":"e_1_2_8_34_1","unstructured":"Mylan Pharmaceuticals. (2018)Zyloprim (allopurinol) [package insert]. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/016084s044lbl.pdf."},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/461870"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/610969"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.4.433"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402235"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.697"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.97"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.5.12.3610"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-39-6-1327"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_2_8_44_1","unstructured":"Sanofi-Aventis. (2009)U.S. LLC. Elitek (rasburicase) [package insert]. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/103946s5083lbl."},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp330"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv317"},{"key":"e_1_2_8_47_1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1542\/peds.82.6.863","article-title":"Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma","volume":"82","author":"Stapleton F.B.","year":"1988","journal-title":"Pediatrics"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.10.031"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13290"},{"key":"e_1_2_8_50_1","first-page":"211","article-title":"Tumour lysis syndrome and acute renal failure in Burkitt's lymphoma. Description of 2 cases and a review of the literature on prevention and management","volume":"45","author":"Veenstra J.","year":"1994","journal-title":"Netherlands Journal of Medicine"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0608-2"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T13:49:33Z","timestamp":1694094573000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1111\/bjh.16278"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16278","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,27]]},"assertion":[{"value":"2019-11-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}